Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders
Pharmacology Research & Perspectives · 2026-06 · 14 (3)
DOI: 10.1002/prp2.70285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 10.06.2026. Verfasst von Aline Frick und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery & Weill Institute for Neuroscience, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Phenylbutyrates, Munc18 Proteins. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Savoy Foundation, STXBP1 Foundation.
Abstract (Originalsprache)
Syntaxin‐binding protein 1 ( STXBP1 ) mutations lead to severe epilepsy, intellectual disability, developmental delay, and movement disorder. Effective treatments for these conditions do not exist. Recent studies in Munc18‐1 ( STXBP1 ) C. elegans models demonstrate that 4‐phenylbutyrate (4‐PBA) or related pharmacological chaperones stabilize Munc18‐1 protein levels and rescue locomotion deficits. These studies suggest a novel treatment strategy for these patients. Here, we used a stxbp1a zebrafish model with a profound movement disorder to screen 4‐PBA and alternative structural analogs identified using artificial intelligence (AI)‐based screening. Automated locomotion assays conducted on larval stxbp1a mutant zebrafish at 5 days post‐fertilization (dpf) confirm and extend the movement disorder endophenotype. Drug treatment (4‐PBA or 16 identified candidates) failed to rescue the stxbp1a mutant zebrafish locomotion deficit. Electrophysiology studies in a stxbp1b zebrafish model characterized by spontaneous seizure activity (i.e., epilepsy) failed to detect a reduction in ictal‐like events with 4‐PBA treatment. Taken together, our results suggest caution in repurposing 4‐PBA or related compounds for the treatment of STXBP1 disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery & Weill Institute for Neuroscience, University of California, San Francisco, San Francisco, California, USA.
- Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.
- Helen Wills Institute of Neuroscience, University of California, Berkeley, San Francisco, California, USA.
ORCID-Profile: Scott C Baraban
Förderung
- NIH HHS
- Savoy Foundation
- STXBP1 Foundation
- National Institutes of Health
Zitieren
APA
Frick, A., Whyte-Fagundes, P., & Baraban, S. C. (2026). Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70285
Vancouver
Frick A, Whyte-Fagundes P, Baraban SC. Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70285
BibTeX
@article{Frick2026,
author = {Frick, Aline and Whyte-Fagundes, Paige and Baraban, Scott C},
title = {Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {3},
doi = {10.1002/prp2.70285}
}
EUVIMED